 |
|
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
Eunjung Yim, Ho Jung An, Uiju Cho, Youngwoo Kim, Seung Hoon Kim, Yeon-Geun Choi, Byoung Yong Shim
Korean J Intern Med. 2018;33(2):432-434. Published online 2016 Jul 7 DOI: https://doi.org/10.3904/kjim.2015.295
|
|
Citations to this article as recorded by
 Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas
Adam Szpechcinski, Malgorzata Szolkowska, Sebastian Winiarski, Urszula Lechowicz, Piotr Wisniewski, Magdalena Knetki-Wroblewska
Cancers.2022; 14(14): 3388. CrossRef A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib
Newton A.C.S. Wong, Christel Garcia-Petit, Adam Dangoor, Nicola Andrew
Cancer Genetics.2022; 268-269: 46. CrossRef Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George
BMC Cancer.2021;[Epub] CrossRef Molecular exploration of paediatric intracranial germinomas from multi-ethnic Singapore
Sharon Yin Yee Low, He Cheng, Ruiyang Zou, Lee Ping Ng, Chik Hong Kuick, Nurfarhanah Bte Syed Sulaiman, Kenneth Tou En Chang, David Chyi Yeu Low, Lihan Zhou, Wan Tew Seow
BMC Neurology.2020;[Epub] CrossRef Gastrointestinal stromal tumor – A review of clinical studies
Ardavan Khoshnood
Journal of Oncology Pharmacy Practice.2019; 25(6): 1473. CrossRef
|